Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alan Marc Kleinfeld is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution for this portfolio is exceptionally focused, involving only 1 distinct examiner and 1 distinct art unit. This narrow scope suggests that the current patent activity is likely centered on a specific biological or pharmaceutical innovation rather than a broad array of diverse technologies, requiring a specialized approach to claim navigation.
JONES, DAMERON LEVEST is the busiest examiner for this entity, holding the 1 busiest examiner pending office action. Because there is only 1 distinct examiner assigned, the progress of the company's intellectual property depends entirely on the interactions with this single official. The involvement of 1 distinct art unit indicates that the legal strategy does not need to account for the differing examination cultures of multiple USPTO departments, allowing for a more streamlined but examiner-dependent approach to securing patent rights. This concentration of 1 pending office action highlights the importance of understanding the specific technical preferences of the assigned reviewer.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632202 | ONE STEP METHODS, KITS, AND SYSTEMS FOR THE MEASUREMENT OF CONCENTRATIONS OF UNBOUND BILIRUBIN IN BIOLOGICAL FLUIDS | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17632202 | ONE STEP METHODS, KITS, AND SYSTEMS FOR THE MEASUREMENT OF CONCENTRATIONS OF UNBOUND BILIRUBIN IN BIOLOGICAL FLUIDS | JONES, DAMERON LEVEST | 1618 | §112 | Final Rejection | — | Pending | Feb 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlan Marc Kleinfeld has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dameron Levest Jones has the most, with 1 of Alan Marc Kleinfeld's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
